Solid pharmaceutical preparation, preparation method therefor and use thereof

A method for preparing a tablet, wherein the method comprises the following steps:

• (a) performing wet granulation after mixing an active ingredient particle, a filler, a binder and a first disintegrant;
• (b) drying a resulting product obtained in step (a);
• (c) dry-blending a resulting product obtained in step (b), a second disintegrant and a lubricant;
• and
• (d) compressing a resulting product obtained in step (c) into the tablet;
• wherein the active ingredient is ((1S,2R,5S)-2-(((5-fluoropyridin-2-yl)oxy)methyl)-8-azabicyclo[3.2.1]octan-8-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone, or a pharmaceutically acceptable salt thereof, or a mixture of both;
• and
• the particle size of the active ingredient particle is D90≤35 μm.

A unit dosage form, wherein based on a total weight of the unit dosage form, the unit dosage form comprises:

• about 10 mg, about 20 mg, or about 40 mg of an active ingredient, wherein the active ingredient is a compound of formula (II);
• about 25 mg to about 150 mg of microcrystalline cellulose;
• about 50 mg to about 300 mg of lactose;
• about 1 mg to about 15 mg of hypromellose;
• about 10 mg to about 50 mg of croscarmellose sodium;
• and
• about 0.5 mg to about 3 mg of magnesium stearate,
• wherein the particle size of the active ingredient is D90=1 μm to 20 μm;
• or
• wherein based on a total weight of the unit dosage form, the unit dosage form comprises:
• 8 mg to 12 mg of an active ingredient, wherein the active ingredient is a compound of formula (II);
• 20 mg to 30 mg of microcrystalline cellulose;
• 46 mg to 56 mg of lactose;
• 2 mg to 4 mg of hypromellose;
• 5 mg to 15 mg of croscarmellose sodium;
• and
• 0.3 mg to 0.7 mg of magnesium stearate,
• wherein the particle size of the active ingredient is D90=1 μm to 20 μm;
• or
• wherein based on a total weight of the unit dosage form, the unit dosage form comprises:
• 18 mg to 22 mg of an active ingredient, wherein the active ingredient is a compound of formula (II);
• 46 mg to 56 mg of microcrystalline cellulose;
• 97 mg to 107 mg of lactose;
• 5 mg to 7 mg of hypromellose;
• 15 mg to 25 mg of croscarmellose sodium;
• and
• 0.8 mg to 1.2 mg of magnesium stearate,
• wherein the particle size of the active ingredient is D90=1 μm to 20 μm;
• or
• wherein based on a total weight of the unit dosage form, the unit dosage form comprises:
• 38 mg to 42 mg of an active ingredient, wherein the active ingredient is a compound of formula (II);
• 97 mg to 107 mg of microcrystalline cellulose;
• 199 mg to 209 mg of lactose;
• 11 mg to 13 mg of hypromellose;
• 35 mg to 45 mg of croscarmellose sodium;
• and
• 1.8 mg to 2.2 mg of magnesium stearate,
• wherein the particle size of the active ingredient is D90=1 μm to 20 μm.